NASDAQ
12.99USD
+0.53 (+4.25%)
We have scored 11 news catalysts on 4D Molecular Therapeutics, Inc. (FDMT) over the past 12 months. The biggest single-day move next to one of them came Jun 10, 2026, when FDMT closed −5.5%: “4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript”. Coverage across the window leans positive (average ticker sentiment +0.33). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
717.6M
P/E
—
EPS
—
Beta
2.91
52W range
6.96-16.93
Day range
12.38–13.03
Open
12.48
Prev close
12.46
Volume
837.2K
Avg volume
933K
Dividend
0.00
IPO
2020-12-11
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about 4D Molecular Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for FDMT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
